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Caveolin-2 tyrosine variant mutant
STAT3 transcriptional activationThe regulatory function of caveolin-2 in signal transducer and activator of transcription 3 (STAT3) signaling
by insulin was investigated. Insulin-induced increase in phosphorylation of STAT3 was reduced by caveolin-2
siRNA. Mutagenesis studies identiﬁed that phosphorylation of tyrosines 19 and 27 on caveolin-2 is required
for the STAT3 activation. Caveolin-2 Y27A mutation decreased insulin-induced phosphorylation of STAT3
interacting with caveolin-2. pY27-Caveolin-2 was required for nuclear translocation of pY705-STAT3 in
response to insulin. In contrast, caveolin-2 Y19A mutation inﬂuenced neither the phosphorylation of STAT3
nor nuclear translocation of pY705-STAT3. pY19-Caveolin-2, however, was essential for insulin-induced DNA
binding of pS727-STAT3 and STAT3-targeted gene induction in the nucleus. Finally, insulin-induced
transcriptional activation of STAT3 depended on phosphorylation of both 19 and 27 tyrosines. Together, our
data reveal that phosphotyrosine-caveolin-2 is a novel regulator for transcriptional activation of STAT3 in
response to insulin.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionSignal transducers and activators of transcription (STATs) are
cytoplasmic proteins that selectively activate nuclear gene transcrip-
tion [1,2]. The activation of STAT proteins involves phosphorylation,
dimerization, nuclear translocation and activation of transcription by
binding to DNA-response elements of target genes [2,3]. STAT
proteins have a Src-homology domain 2 (SH2) near the C-terminus.
The SH2 domain of STATs mediates the selective binding to
phosphotyrosine motifs of speciﬁc ligand receptors [4,5]. During
activation, STATs can be speciﬁcally phosphorylated on both tyrosine
and serine residues [4,6]. The phosphorylation of STAT3 at tyrosine
705 is important for nuclear translocation [6–8]. The phosphorylation
of STAT3 at serine 727 located in a conserved Pro-X-Ser-Pro sequence
has been shown to regulate STAT3-mediated transcriptional activa-
tion [4,6,9,10]. Once the activated STAT3 enters the nucleus, STAT3
binds to a sis-inducible element (SIE) of DNA [8]. After DNA binding,
STAT3 proceeds to transactivate STAT-responsive genes such as Egr1
and JunB [1,11].
STATs have been reported to be activated by receptor tyrosine
kinases (RTKs) [1,2,12]. Putative phosphotyrosine docking sites for
STATs have been identiﬁed on EGF, PDGF, and insulin receptors (IR)82 55 759 9363.
ll rights reserved.[13–15]. However, the mechanism of STAT activation has been
complicated by evidence suggesting that different RTKs potentially
activate different STATs via distinct mechanisms. For instance, EGF
and PDGF receptors appear to activate STAT1 and STAT3 via direct
phosphorylation [16,17], whereas STAT3 activation by IGF-1 or PDGF
receptors has been reported to depend on janus protein-tyrosine
kinase (JAK) activation [15,18]. A conserved phosphorylation site
for mitogen-activated protein kinase (MAPK) is present within the
C-terminus of STAT3 and pS727-STAT3 is phosphorylated by extra-
cellular signal-regulated protein kinases (ERK) in response to EGF
[19–21]. In contrast, other reports indicate that the phosphorylation
and activation of STAT3 are mediated through the phosphatidylino-
sitol 3-kinase (PI3K)/mTOR signaling pathway [22,23]. On the other
hand, independently of both MAPK and PI3K activation, PKC
activation was required for pS727-STAT3 phosphorylation and
transactivation in insulin-mediated signaling [10,24]. Thus, it has
not been well established how the STAT3-mediated insulin signaling
pathway works.
The structural components of caveolae are proteins belonging to
the caveolin family. The three members of this family are caveolin-1,
-2 and -3. Recent studies suggest that caveolins function as scaffolding
proteins to interact with signaling molecules like G-proteins, RTKs,
Src, eNOS, Ras, and ERK [25–27]. Thus, caveolin proteins take part in
various cellular processes. The majority of the research on caveolin
proteins has focused on the functions of caveolin-1 and -3. Caveolin-2,
which is 38% identical and 58% similar to caveolin-1 is widely
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structural role in caveolae formation without any signiﬁcant implica-
tions in cell signaling [25–27,30]. Recent reports show that caveolin-2
can be tyrosine-phosphorylated on 19 by insulin [31,32] and on 19 and
27 by c-Src [32,33]. The tyrosine phosphorylation of caveolin-2
induces the binding of SH2-domain-containing proteins, c-Src, Nck,
and Ras-GAP [32]. However, there have been no reports demonstra-
ting that caveolin-2, per se, can modulate signaling in a manner
similar to caveolin-1 and -3. Furthermore, involvement of caveolin-2
especially in the regulation of STAT3 signaling has not been shown.
We have recently reported that caveolin-2 regulates insulin-
induced cell cycle and identiﬁed pY19-caveolin-2 as a regulator of
insulin-stimulated mitogenesis in Hirc-B cells [31,34]. Hirc-B cells
have been chosen as our model system to explore the regulatory role
of caveolin-2 in insulin signaling due to their high expression of IRs
[31,34,35] and having caveolin-2 as an endogenous caveolin isoform
with no caveolin-1 gene expression [34]. In the studies, we
demonstrated that induction of the caveolin-2 gene was up-regulated
by insulin and caveolin-2 can associate with ERK. The caveolin-2
enhanced the G1 to S phase transition of cell cycle whereas caveolin-1
inhibits when cells were expressed with recombinant caveolin-1.
Moreover, we showed that insulin-triggered phosphorylation of
caveolin-2 at tyrosine 19 and the pY19-caveolin-2 was essential for
interaction of caveolin-2 with phospho-ERK and their nuclear co-
localization. And their interaction and nuclear localization in response
to insulin were inhibited by U0126. Thus, our ﬁndings raised the
possibility that caveolin-2 may act as a regulator for STAT3 activation
and its regulation of cellular functions in insulin signaling pathway.
The present study was conducted to explore that tyrosine phospho-
rylationof caveolin-2 plays a role for STAT3-mediated transcriptional ac-
tivation. Here, we provide evidence that phosphorylation of caveolin-2
at tyrosines 19 and 27 is required for activation, nuclear translocation,
and transcriptional activity of STAT3 in response to insulin.
2. Materials and methods
2.1. Cell culture and treatment
Human insulin receptor-overexpressed rat 1 ﬁbroblast (Hirc-B)
cells were grown in DMEM containing 5 mM D-glucose supplemented
with 10% (v/v) fetal bovine serum (FBS) (Cambrex Bio Science),
100 nM methotrexate (Sigma-Aldrich), and 0.5% gentamycin (Gibco)
in a 5% CO2 incubator at 37 °C [31,34,35]. Cells were serum-starved in
serum-free DMEM containing 0.2% BSA for 4 or 18 h as indicated and
treated with or without 100 nM insulin (Human insulin, Novo
Nordisk) for various period time as indicated.
2.2. Immunoblotting
For protein extraction, cells were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed with RIPA buffer (50 mM
HEPES, 150 mM NaCl, 100 mM Tris–HCl (pH 8.0), 0.25% deoxycholic
acid, 0.1% SDS, 5 mM EDTA, 10 mM NaF, 5 mM DTT, 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM sodium ortho-vanadate,
20 μM leupeptin, and 100 μM aprotinin). The lysate was put on ice for
30min and microcentrifuged at 12,000 rpm for 20min at 4 °C. Aliquots
from the clear supernatant were taken for protein quantiﬁcation as
determined by the Bradford assay (Bio Rad). Equal amounts of samples
(50 μg) were separated on 15% (w/v) SDS-polyacrylamide gels and
transferred to polyvinylidene diﬂuoride (PVDF) membrane (Millipore).
Transfers were blocked overnight at 4 °C with 5% (v/v) nonfat dry milk
in TBS, 0.1% (v/v) Tween 20, and then incubated for 2 h at room
temperature (RT) in the primary antibody. The primary antibodies used
were as follows: caveolin-2 mouse IgG1 (Clone 65, BD 610685; diluted
1/250), caveolin-1 mouse IgG1 (Clone 2297, BD 610407; diluted
1/1000), ERK (BD 610031; 1/2500), and STAT3 (BD 610190; 1/2500)antibodies from BD Transduction Laboratories; pY19-caveolin-2
(ab3417; 1/500) antibody from Abcam; F-actin (sc-1616; 1/200)
antibody from Santa Cruz Biotechnology; phospho-ERK (Thr202 and
Tyr204) (#9101; 1/1000), pS727-STAT3 (#9136; 1/1000), and pY705-
STAT3 (#9135; 1/1000) antibodies from Cell Signaling; M2 FLAG
(F1804; 1/1000) antibody from Sigma. The membranes were washed
with TBS, 0.1% (v/v) Tween 20 and incubated for 1 h at RT in horse-
radish peroxidase-conjugated anti-rabbit (#W4011; 1/15000) or anti-
mouse (#W4021; 1/15000) secondary antibodies (Promega) in 5%
(v/v) nonfat dry milk in TBS, 0.1% (v/v) Tween 20. The immunoblots
were developed using the ECL detection reagent (RPN2106, Amersham
Biosciences).
2.3. Immunoprecipitation
Serum-starved cells were incubated with or without 100 nM insulin
for 10min,washedwith ice-cold PBS and lysed in buffer A containing 1%
Triton X-100,150mMNaCl,10mMTris–HCl (pH 7.4),1mMEDTA,1mM
EGTA (pH 8.0), 0.2 mM sodium ortho-vanadate, 0.2 mM PMSF, 0.5%
Nonidet P-40 (Igepal CA-630, octylphenoxylpolyethoxylethanol,
198596; ICN Biomedicals), and 60 mM n-octylglucoside (OG, 494460,
Calbiochem) [31]. The cell lysates were centrifuged at 12,000 rpm for
20 min at 4 °C and the supernatants were subjected to immunopreci-
pitationwith either anti-caveolin-2, anti-STAT3, or anti-FLAGantibodies.
Lysates were rotated overnight at 4 °C, then 30 μl of protein G plus
Agarose (Calbiochem)was added and themixturewas rotated for 4 h at
4 °C. The immunocomplexes were collected by centrifugation at
12,000 rpm for 10 min 4 °C and washed three times with ice-cold
buffer B (1% Triton X-100,150mMNaCl,10mMTris–HCl (pH 7.4),1mM
EDTA, 1 mM EGTA (pH 8.0), 0.2 mM sodium ortho-vanadate, 0.2 mM
PMSF, 0.5% Nonidet P-40). After the ﬁnal wash the pellet was
resuspended in 30 μl of 2× SDS-PAGE sample buffer. Immunoprecipi-
tated samples were then resolved, separated by SDS-PAGE, and
subjected to immunoblot analyses using the speciﬁc antibodies against
proteins of interest.
2.4. Silencing of the caveolin-2
The small interfering RNAs (siRNAs) were designed to target the
following sequences: scramble control; 5′-GGAAAGACUGUUC-
CAAAAA-3′, caveolin-2 siRNA duplexes; sense (GUAAAGACCUGC-
CUAAUGGUU) and antisense (5′-PCCAUUAGGCAGGUCUUUACUU).
The siRNA duplexes were synthesized and puriﬁed by Dharmacon
Research, Inc. Brieﬂy, transfection of siRNA duplexes was carried out
using DhamaFECT Transfection Reagents (Dharmacon) for 48 h. The
transfected cells were serum-starved for 4 h and followed by
stimulation with or without 100 nM insulin for 10 min. Cells were
then subjected to immunoblot analysis and processed for immuno-
ﬂuorescence microscopy as described below.
2.5. Plasmids
A full-length caveolin-2 cDNA (NM_131914) was subcloned into
pcDNA3 vector (Invitrogen) [31]. Constructs encoding wild type (WT)
caveolin-2 and point mutants including Y19A, Y27A, and Y19A/Y27A
were generated by PCR mutagenesis using mutated oligonucleotides.
FLAG-tagged caveolin-2 variants were cloned via PCR-based gateway
cloning method as described previously [36]. Brieﬂy, the caveolin-2
variants were ampliﬁed, cloned into pDONR207 vectors, and con-
verted into pDS_EGFP-XB (a gift from Dr. Tobias Meyer, Stanford
University) or self-made pDS_FLAG-XB vectors. The pDS_FLAG-XB
vectors were generated by exchanging EGFP sequences of pDS_EGFP-
XB vectors with FLAG sequences using an EZ change site-directed
mutagenesis kit (Enzynomics, Daejeon, Korea). The plasmids were
transiently transfected into cells using the Lipofectamine LTX
transfection reagent (Invitrogen) as per the manufacturer's
Fig. 1. Phosphorylation of STAT3 is decreased by caveolin-2 siRNA and tyrosine mutants.
(A) Hirc-B cells were transfected with scramble or caveolin-2 siRNAs for 48 h. The cells
were treated with or without insulin (100 nM) for 10 min.Whole cell lysates (WCL) were
subjected to immunoblotting using antibodies speciﬁc for pS727-STAT3, pY705-STAT3,
STAT3, caveolin-2, caveolin-1 and actin.Numerical data represent themean±S.E. of results
that were repeated three times each with similar results; ⁎ comparison with their scram-
ble controls, Pb0.05. (B) Cells were transfected with pcDNA3 vector, wild type (WT)
caveolin-2, Y19A-caveolin-2, Y27A-caveolin-2, or Y19A/Y27A-caveolin-2. Thirty-six hours
post-transfection, the cells were treatedwith orwithout insulin (100 nM) for 10min.WCL
were subjected to immunoblot analysis with anti-pS727-STAT3, anti-pY705-STAT3, anti-
STAT3, anti-pY19-caveolin-2, anti-caveolin-2, and anti-actin antibodies as indicated. The
results represent the mean±S.E. of four independent experiments.
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into boiling sample buffer. Recombinant expression was conﬁrmed by
immunoblotting.
2.6. Fluorescence microscopy and quantitative detection of ﬂuorescence
staining
Effects of insulin and caveolin-2 variants on cellular translocation
of caveolin-2, pY705-STAT3, and phospho-ERK were investigated by
immunostaining cells. Brieﬂy, transfected cells were serum-starved
for 4 h in DMEM containing 0.2% BSA. Cells were then incubated with
or without 100 nM insulin for 10min, washed twice with ice-cold PBS,
and ﬁxed with 3.7% paraformaldehyde in PBS for 20 min at RT. The
ﬁxed cells were rinsed with PBS and incubated with 0.1% Triton X-100
in PBS for 30 min. Permeabilized cells were rinsed with PBS, incu-
bated with 1% BSA in PBS for 30 min and then with anti-FLAG, anti-
pY705-STAT3, and anti-phospho-ERK antibodies in 1% BSA in PBS for
2 h at RT. After washing three times with PBS, the primary antibodies
were detected with either Alexa Fluor®488-conjugated anti-mouse
(1/250 dilution) (Invitrogen) or TRITC-conjugated anti-rabbit (1/100
dilution) (Sigma) IgG antibodies for FLAG, pY705-STAT3 and phos-
pho-ERK as indicated. Nuclei were ﬂuorescently labeled with 4′,
6-diamidino-2-phenylinodole (DAPI) (D8417: Sigma) for 15min at RT.
The coverslips were then washed and mounted on glass slides.
Fluorescent images were obtained using appropriate ﬁlters on an
Olympus BX51microscope and imagedwith an Olympus DP-71 digital
camera with an image processing system equipped with Image-
ProPlus 6.1 (MediaCybernetics). Neither labeling in the absence of the
primary antibody nor cross-reactivity between secondary and
primary antibodies was observed. Fluorescence staining was quanti-
ﬁed by image analysis performed using ImageJ software (National
Institutes of Health) as previously described [31]. The DAPI staining
mask was used to deﬁne the nuclear region of interest (ROI). Brieﬂy,
using the Image Calculator from ImageJ, the DAPImaskwas subtracted
from the merge mask to create a staining mask deﬁning the
cytoplasmic ROI. Nuclear and cytoplasmic staining intensities were
compared to give the nuclear:cytoplasmic ratio. Averages and
standard errors were computed over 5 images per condition for a
minimum of 200 cells per condition.
2.7. DNA binding assay
Whole cell lysateswere prepared using lysis buffer (1% Triton X-100,
50 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA, 0.2 mM sodium ortho-
vanadate, 0.2 mM PMSF, and 0.5% Nonidet P-40). The whole cell lysates
were incubated with 10 μg of SIE-oligonucleotide agarose beads (Santa
Cruz) for overnight at 4 °C. After incubation, the beads were washed
with binding buffer (10mMTris (pH 7.5), 50mMNaCl,1mMDTT,1mM
EDTA, 5% glycerol, and 1 μg/ml poly dI-dC), and then proteins were
eluted from beads with elution buffer (same as the binding buffer but
containing 150 mM NaCl). The SIE bead-precipitated proteins were
separated by SDS-PAGE and then transferred to PVDF membranes for
immunoblotting with anti-pS727-STAT3 and anti-STAT3 antibodies.
2.8. Reverse transcription-PCR
Total RNA was extracted with TRIzol reagent (SolGent Co., Ltd.)
according to the manufacturer's instructions. cDNA was genera-
ted using reverse transcription kit (Accupower RT PreMix,
Bioneer). The cDNA was used as the template for the subsequent
PCR ampliﬁcation. PCR primers were for glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH): 5′-ACCACCATGGAGAAGGCTGG-3′
and 5′-CTCAGTGTAGCCCAGGATGCC-3′; JunB: 5′-ACTCTTACG-
CAGCGGCAGG-3′ and 5′-AGTAACTGCTGAGGTTGGTGTAGACC-3′;
Erg1: 5′-GACAGCAGTCCCATTTACTCAGCT-3′ and 5′-TGTCACAGG-
CAAAAGGCTTCTC-3′. PCR was performed using AccuPower PCRPreMix (Bioneer) kit. The PCR fragments were separated by running
on 1% agarose gels.
2.9. Luciferase reporter assay
STAT3 TransLucent Reporter Vector (STAT3-Luc) to monitor
transcription factor binding activity of STAT3 was purchased from
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the Lipofectamine LTX reagent (Invitrogen) with 0.5 μg of plasmid
DNA (STAT3-Luc) along with the control pcDNA3, pcDNA3+WT
caveolin-2, pcDNA3+Y19A-caveolin-2, pcDNA3+Y27A-caveolin-2,
or pcDNA3+ Y19A/Y27A-caveolin-2 in each well of 24-well plates.
The Renilla reporter construct pRL-TK (Promega) was used to
normalize the transfection efﬁciency. The cells were incubated for
24 h in DMEM containing 10% FBS and then serum-starved for 4 h in
DMEM containing 2% BSA prior to stimulationwith or without 100 nM
insulin for 16 h. The cells were washed twice with ice-cold PBS and
lysed in 100 μl/well of passive lysis buffer (Promega). Luciferase
activity was measured using a dual-luciferase reporter assay system
(Promega).Fig. 2. Y27A-Caveolin-2 mutant decreases phosphorylation of STAT3 interacting with caveo
(100 nM) for 10 min. Equal amounts of WCL were immunoprecipitated with anti-caveolin-2
anti-pY705-STAT3, anti-STAT3, anti-pY19-caveolin-2, anti-caveolin-2, and anti-caveolin-1
precipitation experiments with anti-STAT3 or anti-caveolin-2 antibodies is shown. (B) Cel
Y27A-caveolin-2, or FLAG-Y19A/Y27A-caveolin-2 were treated with or without insulin (10
antibodies and subjected to immunoblot analysis with anti-pS727-STAT3, anti-pY705-STAT
represent the mean±S.E. of results that were repeated three times each with similar resul2.10. Densitometry analysis
Chemiluminescent images of immunoblots were analyzed by
scanning densitometry using a Kodak Gel Logic 100 Imaging System
(Eastman Kodak Co.). Multiple exposure of each blot was used to
obtain gray-scale images of each chemiluminescent band. Bands were
visualized on a UV transilluminator and photographed.
2.11. Statistical analysis
Data are expressed as mean±S.E. An unpaired Student's t test was
used to compare treatment groups with signiﬁcance established at a
level of pb0.05.lin-2. (A) Hirc-B cells were serum-starved for 18 h and treated with or without insulin
or anti-STAT3 antibodies and subjected to immunoblot analysis with anti-pS727-STAT3,
antibodies as indicated. A representative result from three independent immuno-
ls expressing pDS_FLAG-XB vector, FLAG-WT caveolin-2, FLAG-Y19A-caveolin-2, FLAG-
0 nM) for 10 min. WCL were immunoprecipitated with anti-caveolin-2 or anti-FLAG
3, anti-STAT3, anti-FLAG, and anti-caveolin-2 antibodies as indicated. Numerical data
ts; ⁎ comparison with their respective vector controls, PN0.05. ⁎⁎Pb0.001.
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3.1. Phosphorylation of caveolin-2 at tyrosines 19 and 27 is important for
pS727-STAT3 activation
To evaluate the role of caveolin-2 in STAT3 activation by insulin,
cells were transfected with caveolin-2 speciﬁc siRNA. As shown in
Fig. 1A, the caveolin-2 siRNAs effectively depleted caveolin-2 protein
by over 80% of levels detected in the scramble control. Knockdown of
caveolin-2 decreased phosphorylation of pS727- and pY705-STAT3 by
1.7 and 1.4 fold, respectively in response to insulin (Fig. 1A). As
previously demonstrated [31,34], caveolin-1 was not detected and
exhibited no changes by insulin and caveolin-2 siRNA in Hirc-B cells.
Thus, the results show that caveolin-2 is required for insulin-
stimulated phosphorylation of STAT3.
Caveolin-2 contains a consensus sequence (QLFMADDSpY) for
phosphorylation by a tyrosine kinase at tyrosine 19 and a conserved
SH2 domain-binding motif (pYADP) at tyrosine 27 [32,33]. To
investigate how pY19- and pY27-caveolin-2 function in insulin-
induced STAT3 signaling, we generated three tyrosine mutants of
caveolin-2. As demonstrated in Fig. 1B, panel 4, Y19A- and Y19A/
Y27A-caveolin-2mutants are no longer phosphorylated at tyrosine 19.
The caveolin-2 variants induced 2.1–3.4 fold increases in phosphor-
ylation of pS727-STAT3 without insulin stimulation as compared toFig. 3. Y27A-Caveolin-2mutant prevents nuclear translocation of pY705-STAT3. Conﬂuent cel
FLAG-Y19A-caveolin-2, FLAG-Y27A-caveolin-2, or FLAG-Y19A/Y27A-caveolin-2. Thirty-six ho
Cells were stained with anti-FLAG and anti-pY705-STAT3 antibodies followed by Alexa Flu
visualize the nucleus. pY705-STAT3 nuclear translocation was quantiﬁed by ImageJ. The
independent experiments. A minimum of 200 cells per condition were counted. Red: pY
variants+DAPI.endogenous caveolin-2 (vector control) (Fig. 1B). Wild type (WT)
caveolin-2 increased phosphorylation of pS727-STAT3 by 1.6 fold with
insulin stimulation as compared to the basal increased level by
endogenous caveolin-2. Y19A- or Y27A-Caveolin-2 mutants caused
the same increases (1.6 fold) in the insulin-induced phosphorylation
of pS727-STAT3 as observed by WT caveolin-2. Y19A/Y27A-Caveolin-
2, however, decreased insulin-induced phosphorylation of pS727-
STAT3 below the control endogenous caveolin-2 level. These results
suggest that phosphorylation of caveolin-2 at tyrosines 19 as well as
27 is required for insulin-induced activation of pS727-STAT3. In
contrast, insulin-stimulated phosphorylation of pY705-STAT3 exhib-
ited no detectable changes by the caveolin-2 variants (Fig. 1B).
3.2. Caveolin-2 Y27A mutation decreases phosphorylation of
caveolin-2-associated STAT3
As we investigated caveolin-2 interaction with STAT3, STAT3
association with caveolin-2 was observed in untreated cells and
the amount of STAT3 interacting with caveolin-2 was not changed
by insulin (Fig. 2A). Insulin triggered phosphorylation of pY19-
caveolin-2 (Fig. 2A. left panel 4) as previously demonstrated [31] and
increased the amount of pY19-caveolin-2 interacting with STAT3
(Fig. 2A, right panel 1). The amount of pS727- and pY705-STAT3
associated with caveolin-2 was increased by insulin. Caveolin-2 orls grown on coverslips were transfectedwith pDS_FLAG-XB vector, FLAG-WTcaveolin-2,
urs post-transfection, the cells were treatedwith orwithout insulin (100 nM) for 10min.
or®488- or TRITC-conjugated antibodies, respectively. DNA was stained using DAPI to
results represent the mean±S.E. from analysis of ﬁve separate ﬁeld image of ﬁve
705-STAT3, green: FLAG-caveolin-2 variants, merge: pY705-STAT3+FLAG-caveolin-2
Fig. 4. Y19A-Caveolin-2 mutant attenuates phosphorylation of ERK interacting
caveolin-2. Hirc-B cells expressing pDS_FLAG-XB vector, FLAG-WT caveolin-2, FLAG-
Y19A-caveolin-2, FLAG-Y27A-caveolin-2, or FLAG-Y19A/Y27A-caveolin-2 were treated
with or without insulin (100 nM) for 10 min. WCL were immunoprecipitated with anti-
caveolin-2 or anti-FLAG antibodies and subjected to immunoblot analysis with anti-
phospho-ERK, anti-ERK, anti-FLAG, and anti-caveolin-2 antibodies as indicated.
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we explored the effect of caveolin-2 tyrosine mutation on the
phosphorylation of pS727- and pY705-STAT3 using FLAG-taggedFig. 5. Y19A-Caveolin-2 mutant impedes nuclear localization of phospho-ERK. Conﬂuent cell
FLAG-Y19A-caveolin-2, FLAG-Y27A-caveolin-2, or FLAG-Y19A/Y27A-caveolin-2. Thirty-six ho
Cells were stained with anti-phospho-ERK antibody followed by TRITC-conjugated antibody.
was quantiﬁed by ImageJ. The results represent the mean±S.E. from analysis of ﬁve separat
were counted. Red: phospho-ERK, merge: phospho-ERK+DAPI.caveolin-2 variants, the caveolin-2 variants induced 2.8–4.7 and
4.8–5.3 fold increases in the phosphorylation of pS727- and pY705-
STAT3, respectively without insulin stimulation (Fig. 2B). Insulin-
induced phosphorylation of the caveolin-2-bound pS727- and
pY705-STAT3 was 1.6–2.6 fold increased by WT and Y19A-caveolin-2
as compared to the increases by endogenous caveolin-2 (vector
control). Caveolin-2 Y27Amutation, however, markedly decreased the
phosphorylation of STAT3 close to the basal level by endogenous
caveolin-2 in response to insulin. The reduction by Y27A-caveolin-2
was reconﬁrmed by expression of double mutant, Y19A/Y27A-
caveolin-2 exhibiting almost the same degree of decrease as observed
by Y27A-caveolin-2 (Fig. 2B). Together, these data suggest that there is
a sub-pool of STAT3 that becomes phosphorylated while bound to
caveolin-2, and that this activation requires phosphorylation of
caveolin-2 on tyrosine 27 in response to insulin.
3.3. Caveolin-2 Y27A mutation impairs nuclear translocation of
pY705-STAT3
Transcriptional activation of STAT3 is characterized by nuclear
translocation of pY705-STAT3 [1]. To study the functional signiﬁcance
of two tyrosine-phosphorylated forms of caveolin-2 on the transloca-
tion of pY705-STAT3, we examined effect of FLAG-tagged caveolin-2s grown on coverslips were transfected with pDS_FLAG-XB vector, FLAG-WT caveolin-2,
urs post-transfection, the cells were treatedwith orwithout insulin (100 nM) for 10min.
DNAwas stained using DAPI to visualize the nucleus. Phospho-ERK nuclear translocation
e ﬁeld images of three independent experiments. A minimum of 200 cells per condition
Fig. 6. Y19A-Caveolin-2 mutant decreases DNA binding of pS727-STAT3 and STAT3-
mediated immediate early gene induction. (A) Hirc-B cells expressing pDS_FLAG-XB
vector, FLAG-WT caveolin-2, FLAG-Y19A-caveolin-2, or FLAG-Y19A/Y27A-caveolin-2
were treated with or without insulin (100 nM) for 10 min. The DNA binding activity of
the cell lysates were detected as described above. The results represent the mean±S.E.
of three independent experiments. (B) Cells were transfected with pcDNA vector, WT
caveolin-2, Y19A-caveolin-2, or Y19A/Y27A-caveolin-2. Thirty-six hours post-transfec-
tion, the cells were treated with or without insulin (100 nM) for 60 min. Egr-1 and JunB
mRNA levels were analyzed by the RT-PCR. Numerical data represent the mean±S.E. of
results that were repeated three times each with similar results. GAPDH was co-
ampliﬁed as the internal control.
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STAT3 in response to insulin. Insulin triggered nuclear translocation
of pY705-STAT3 in vector control. While WT and Y19A-caveolin-2
promoted translocation of pY705-STAT3 to the nucleus, Y27A- and
Y19A/Y27A-caveolin-2 blocked the nuclear translocation in response
to insulin (Fig. 3). Consistent with the results, quantitative data
showed decreases in nuclear:cytoplasmic ratios of pY705-STAT3
staining by Y27A- and Y19A/Y27A-caveolin-2 mutants in response
to insulin. Whenwe examined nuclear translocation of the caveolin-2
variants, insulin re-localized WT caveolin-2 to the nucleus. However,
Y19A-, Y27A-, and Y19A/Y27A-caveolin-2 remained in the cytoplasm
suggesting both pY19- and pY27-caveolin-2 are required for nuclear
localization of caveolin-2 in response to insulin. Thus, our data show
that phosphorylation of caveolin-2 at tyrosine 27 inﬂuences insulin-
induced nuclear translocation of pY705-STAT3.
3.4. pY19-Caveolin-2 regulates nuclear translocation of phospho-ERK
Since pY27-caveolin-2 inﬂuenced insulin-induced phosphoryla-
tion of STAT3 interacting with caveolin-2 as demonstrated in Fig. 2, we
next investigated if pY27-caveolin-2 affects phosphorylation of ERK,
which is known to activate pS727-STAT3 [19–21], using FLAG-tagged
caveolin-2 variants (Fig. 4). Caveolin-2 variants increased phospho-
rylation of ERK associated with caveolin-2 (3.0–3.8 fold) without
insulin stimulation (Fig. 4). The phosphorylation of ERK was 2.0–2.4
fold increased by WT and Y27A-caveolin-2 as compared to the
increase by endogenous caveolin-2 (vector control) in response to
insulin. In our previous study, we showed that phosphorylation of ERK
associated with caveolin-2 is increased by pY19-caveolin-2 [31].
Consistent with the ﬁnding, Y19A-caveolin-2 mutation decreased the
phosphorylation of ERK and the reduction was reconﬁrmed by Y19A/
Y27A-caveolin-2 double mutant (Fig. 4). Thus, our present data
reconﬁrm and reveal that pY19-caveolin-2, but not pY27-caveolin-2, is
essential for insulin-induced phosphorylation of ERK interacting with
caveolin-2. Together, the data demonstrated in Fig. 2B point out that
pY27-caveolin-2, but not pY19-caveolin-2, is required for phospho-
rylation of STAT3 interacting with caveolin-2 in response to insulin.
In addition to insulin-triggered interaction between pY19-
caveolin-2 and phospho-ERK, insulin re-localized the pY19-caveolin-2
and phospho-ERK to the nucleus [31]. To examinewhether the nuclear
localization of phospho-ERK is affected by phosphorylation of
caveolin-2 on tyrosines 19 and 27, the effect of caveolin-2 tyrosine
mutants on immunoﬂuorescence localization of phospho-ERK was
investigated. In untreated cells, phospho-ERK was localized at the
cytoplasm (Fig. 5). Insulin triggered translocation of phospho-ERK to
the nucleus in vector control andWT caveolin-2-transfected cells. The
localization of phospho-ERK, however, was retarded by Y19A- and
Y27A-caveolin-2 mutation (Fig. 5). The retardation of phospho-ERK
was reconﬁrmed by Y19A/Y27A-caveolin-2 double mutation. Con-
sistent with the results, quantitative data showed decreases in
nuclear:cytoplasmic ratios of phospho-ERK staining by Y19A-, Y27A-
and Y19A/Y27A-caveolin-2 mutants in response to insulin. Thus, the
data show that pY19- and pY27-caveolin-2 are required for the
insulin-induced nuclear localization of ERK.
3.5. pY19-Caveolin-2 enhances DNA binding activity of pS727-STAT3 and
STAT3-induced immediate early gene transcription
Although nuclear translocation of phospho-ERK was impaired by
Y19A-caveolin-2, STAT3 became phosphorylated and pY705-STAT3 re-
localized to the nucleus in response to insulin (Figs. 2–5). It has been
reported that ERK phosphorylates pS727-STAT3 [19–21], which, in
turn, promotes STAT3-mediated transcriptional activation [4,6,9,10].
Thus, we postulated that the retardation in nuclear translocation of
phospho-ERK by Y19A-caveolin-2 leads to impairment of pS727-
STAT3 function in the nucleus. Accordingly, we investigated the effectof pY19-caveolin-2 in insulin-induced STAT3 regulation in the
nucleus. First, to examine insulin-induced DNA binding activity of
STAT3, a DNA binding assay using SIE oligo-agarose beads was
performed. As shown in Fig. 6A, insulin stimulated DNA binding of
STAT3, which was not observed in the absence of insulin stimulation
(vector control). When the blot was stripped and re-probed with anti-
phospho-STAT3 antibodies, pS727-STAT3, but not pY705-STAT3 (data
not shown), was detected. WT caveolin-2 overexpression increased
DNA binding of STAT3 but the binding activity was not changed by
insulin stimulation. Further, the STAT3 DNA binding was not affected
by Y19A- and Y19A/Y27A-caveolin-2 mutants (Fig. 6A, panel 2).
When DNA binding of pS727-STAT3 was examined, the caveolin-2
variants induced 4.7–6.3 fold increases without insulin stimulation
(Fig. 6A, panel 1). DNA binding of pS727-STAT3 in response to
insulin was 1.5 fold increased by WT caveolin-2 as compared to
the increase by endogenous caveolin-2 (vector control). Y19A- and
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the endogenous caveolin-2 level. Thus, these data reveal that pY19-
caveolin-2 regulates insulin-induced DNA binding of pS727-STAT3 in
the nucleus.
Next, to investigate a regulatory role of pY19-caveolin-2 in STAT3-
induced early gene transcription, the immediate early gene induction
in response to insulin was examined by RT-PCR analysis. As shown in
Fig. 6B, insulin-elicited Egr-1 and JunB transcription was increased by
WT caveolin-2. The Egr-1 and JunB transcription, however, was
decreased to the control levels by Y19A- and Y19A/Y27A-caveolin-2
mutants. Taken together, our ﬁndings indicate that pY19-caveolin-2
regulates insulin-induced DNA binding activity of pS727-STAT3 and
STAT3-targeted immediate early gene induction in the nucleus.
3.6. Phosphotyrosine-caveolin-2 regulates transcriptional activation of
STAT3
To further evaluate whether caveolin-2 controls the transcriptional
activation of STAT3 by insulin, we performed a reporter gene assay
using a luciferase reporter construct containing STAT3-binding sites.
Insulin enhanced STAT3-mediated transcriptional activation by a 1.9
fold (Fig. 7A). However, down-regulation of caveolin-2 caused 63%
suppression in the insulin-induced STAT3-mediated transcriptional
activity. When the effect of tyrosine phosphorylation of caveolin-2
was examined, STAT3-mediated transcriptional activity was 1.3–1.7
fold up-regulated by caveolin-2 variants as compared to endogenous
caveolin-2 (vector control) without insulin stimulation (Fig. 7B). WTFig. 7. Caveolin-2 siRNA and caveolin-2 tyrosine mutants attenuate transcriptional
activation of STAT3. (A) Hirc-B cells were co-transfected with scramble or caveolin-2
siRNAs and STAT3-Luc with pRL-TK vectors for 48 h. The cells were treated with or
without insulin (100 nM) for 16 h. Luciferase activity was measured with the dual-
luciferase assay system and data were presented as the mean±S.E. of three
independent experiments performed. (B) Cells were co-transfected with pcDNA vector,
WT caveolin-2, Y19A-caveolin-2, Y27A-caveolin-2, or Y19A/Y27A-caveolin-2 and
STAT3-Luc with pRL-TK vectors for 48 h. The cells were treated with or without insulin
(100 nM) for 16 h. The results represent the mean±S.E. of three independent
experiments.Caveolin-2 increased the STAT3-mediated transcriptional activation
by 1.5 fold with insulin stimulation as compared to the basal increased
level by endogenous caveolin-2. Y19A-, Y27A- or Y19A/Y27A-
caveolin-2, however, completely inhibited the transcriptional activa-
tion below the basal level by endogenous caveolin-2. Thus, these data
demonstrate that phosphorylation of caveolin-2 at tyrosines 19 and 27
is required for the transcriptional activation of STAT3 in response to
insulin.
4. Discussion
Our ﬁrst investigation for the functional role of insulin-induced
tyrosine phosphorylation of caveolin-2 has revealed that phospho-
rylation of pY19-caveolin-2 is required for ERK-mediated mitogenic
regulation of insulin signaling [31]. The present results identify that
pY27- and pY19-caveolin-2 regulate STAT3 activation. To deﬁne the
regulatory mechanism by pY27- and pY19-caveolin-2 involved in
STAT3 activation in insulin signaling, we investigated effect of
caveolin-2 tyrosine variant mutants. Mutation of either of these two
tyrosines to alanine does not inﬂuence insulin-induced activation of
pY727- and pY705-STAT3, but double mutation of tyrosines 19 and 27
completely inhibited the phosphorylation of pS727-STAT3. Thus, the
present results demonstrate that phosphorylation of caveolin-2 at
tyrosines 19 and 27 is required for pS727-STAT3 activation.
One of the well known functions of tyrosine phosphorylation is to
confer docking sites for SH2 domain-containing proteins. STATs have a
SH2 domain near the C-terminus [4,5]. Caveolin-2 contains a
conserved motif at tyrosine 27 for recognition by SH2 domain-
containing proteins [32,33]. To our knowledge, our data show the ﬁrst
demonstration that caveolin-2 interacts with STAT3. Of interest,
insulin did not affect the total amount of STAT3 that is associated
with caveolin-2. However, insulin increased phosphorylation of STAT3
interacting with caveolin-2. The phosphorylation of pS727- and
pY705-STAT3 was markedly decreased by Y27A-caveolin-2 mutation.
In parallel, insulin-induced nuclear translocation of pY705-STAT3 was
blocked by Y27A-caveolin-2. These results collectively reveal that
pY27-caveolin-2 is critical not only for phosphorylation of STAT3
interacting with caveolin-2 but also nuclear translocation of pY705-
STAT3 in response to insulin.
In contrast to the results by Y27A-caveolin-2, Y19A-caveolin-2
mutation exhibited no effect on the phosphorylation of STAT3 and
nuclear localization of pY705-STAT3. We have previously shown that
insulin promotes nuclear translocation of pY19-caveolin-2 and phos-
pho-ERK and demonstrated that their nuclear translocation is inhibited
by U0126 [31]. The present data demonstrate that Y19A-caveolin-2 re-
mains in cytoplasm in response to insulin and that the Y19A-caveolin-2
attenuates translocation of phospho-ERK to the nucleus. Since pS727-
STAT3 is known to be phosphorylated by ERK [19–21], we investigated
whether thenuclear localized STAT3carries on transcriptional activation
in the nucleus where pY19-caveolin-2 and phospho-ERK are absent.
Mutation of caveolin-2 at tyrosine 19 markedly decreased insulin-
induced DNA binding of pS727-STAT3 in the nucleus. Moreover, insulin-
induced STAT3-responsive induction of Egr-1 and JunB genes was also
dependent on phosphorylation of pY19-caveolin-2. Thus, our data
suggest that the impairmentof nuclear translocationof phospho-ERKby
Y19A-caveolin-2mutation leads to the attenuationon theERK-mediated
phosphorylation of pS727-STAT3 required for DNA binding and early
gene transcription of STAT3 in the nucleus. Finally, our results from the
STAT3-speciﬁc luciferase reporter assay demonstrate that phosphoryla-
tion of caveolin-2 at tyrosines 19 and 27 is required for insulin-
stimulated transcriptional activation of STAT3. Collectively, the present
data support that insulin-induced STAT3-dependent transcription is
regulated by phosphorylation of caveolin-2 at tyrosines 19 as well as 27.
In summary, the present study suggests that pY27-caveolin-2 re-
localizes pY705-STAT3 to the nucleus in response to insulin. pY19-
Caveolin-2-regulated ERK activates pS727-STAT3 in the nucleus,
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pS727-STAT3 and, in turn, STAT3-mediated transcriptional activation.
Thus, the phosphotyrosine-caveolin-2 acts as an important compo-
nent in STAT3 transcriptional activation regulated by cross-talk among
caveolin-2, ERK and STAT3 in insulin signaling. STAT3 is constitutively
activated in many human cancers [37,38]. Oncogenic STAT3, which is
not dependent on phosphorylation by JAK, cannot be down-regulated
by SOCS1 [39]. Caveolin-2 is widely presented in both normal and
tumor cells [29]. Therefore, the inhibition of tyrosine phosphorylation
of caveolin-2 could be a novel molecular target for the regulation of
oncogenic STAT3 in various cancers.
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